市场调查报告书
商品编码
1351541
血管闭合装置市场规模 - 依装置类型(主动血管闭合装置、被动血管闭合装置)、按通路(股骨、桡动脉)、依最终用途、预测,2023 年至 2032 年。Vascular Closure Device Market Size - By Device Type (Active Vascular Closure Devices, Passive Vascular Closure Devices), By Access (Femoral, Radial), By End-use, Forecast, 2023 - 2032. |
在血管闭合技术持续进步的推动下,2023 年至 2032 年全球血管闭合装置市场规模将以 6.5% 的复合年增长率成长。血管闭合装置设计和技术的不断进步是推动力。製造商正在开发安全性更高、易于使用且降低併发症发生率的设备。
例如,2023 年 3 月,Vivasure Medical 获得 FDA 试验器械豁免 (IDE) 许可,标誌着其 PerQseal 器械的临床研究向前迈出了重要一步。为了支持开发这种旨在解决大口径动脉血管封堵中出血併发症的创新封堵系统,该公司从Haemonetics Corp 获得了3000 万欧元(约3200 万美元)的战略投资。这些创新旨在满足特定需求不同患者群体和临床场景的研究,这将有助于增强未来十年的产业前景。
整个血管闭合装置市场根据装置类型、通路、最终用途和地区进行分类。
2023-2032 年,被动血管闭合装置产业将呈现 6.4% 的成长率。被动血管闭合装置由于其微创性质并且能够减少涉及动脉穿刺的手术中的併发症,因此在医疗领域越来越受欢迎。这些设备提供了一种方便有效的方法来实现止血,无需主动手动压迫,从而缩短恢復时间,减少患者不适,并改善患者治疗结果,最终推动它们在医疗保健专业人员中得到越来越多的采用。
在通路方面,到2032年,股动脉段血管闭合装置的市占率复合年增长率将达到6.6%。股动脉相对较大且容易进入,使其适合广泛的介入性手术。 VCD 可以更有效地部署在股骨通路中,确保穿刺部位安全闭合,降低出血等併发症的风险,并使患者比其他接入点更快康復。这使得股动脉通路成为许多临床场景中 VCD 应用的首选。
门诊手术中心可能会主导血管闭合器械行业的最终使用格局,并在2023 年至2032 年间呈现6.4% 的复合年增长率。ASC 为包括血管介入治疗在内的许多门诊手术提供了传统医院的经济高效的替代方案。血管闭合装置对于最大限度地减少术后併发症和促进患者更快出院至关重要,符合 ASC 模型的效率和患者便利性目标。随着 ASC 中进行的微创血管手术数量的增加,导致这种情况下对这些设备的需求不断增长。
欧洲血管闭合器械产业正在经历大幅成长,2023-2032 年复合年增长率将达到 6.3%。欧洲人口老化不断加剧,导致心血管手术增加。促进病人安全的严格法规和先进医疗技术的采用推动了对更安全、更有效的闭合方法的需求。此外,医疗保健专业人员意识的提高以及该地区主要市场参与者的存在也有助于该行业在欧洲的强劲增长。
Global Vascular Closure Device Market size will expand at 6.5% CAGR from 2023 to 2032, driven by consistent advancements in vascular closure technologies. Continuous advancements in the design and technology of vascular closure devices are a driving force. Manufacturers are developing devices with improved safety profiles, ease of use, and reduced complication rates.
For instance, in March 2023, Vivasure Medical was granted FDA investigational device exemption (IDE) clearance, marking a significant step forward in its clinical study of the PerQseal device. To support the development of this innovative closure system designed to address bleeding complications in large-bore arterial vessel closure, the company secured a strategic investment of €30 million (~US$32 million) from Haemonetics Corp. These innovations aim to address the specific needs of different patient populations and clinical scenarios, which will help strengthen the industry outlook over the next ten years.
The overall vascular closure device market is categorized based on device type, access, end-use, and region.
The passive vascular closure device industry will demonstrate a 6.4% growth rate over 2023-2032. Passive vascular closure devices are gaining popularity in the medical field due to their minimally invasive nature and ability to reduce complications in procedures involving arterial punctures. These devices offer a convenient and effective way to achieve hemostasis without the need for active manual compression, leading to shorter recovery times, decreased patient discomfort, and improved patient outcomes, ultimately driving their increasing adoption among healthcare professionals.
In terms of access, the vascular closure device market share from the femoral segment will record 6.6% CAGR through 2032. The femoral artery is relatively large and accessible, making it suitable for a wide range of interventional procedures. VCDs can be deployed more effectively in femoral access, ensuring secure closure of the puncture site, reducing the risk of complications such as bleeding, and enabling faster patient recovery than other access points. This makes femoral access a preferred choice for VCD applications in a number of clinical scenarios.
Ambulatory Surgical Centers could dominate the end-use landscape of the vascular closure device industry and exhibit a 6.4% CAGR between 2023 and 2032. ASCs offer cost-effective alternatives to traditional hospitals for many outpatient procedures, including vascular interventions. Vascular closure devices are crucial in minimizing post-procedure complications and facilitating quicker patient discharge, aligning with the ASC model's goals of efficiency and patient convenience. This, along with the increasing volume of minimally invasive vascular procedures performed in ASCs, contributes to the rising demand for these devices in this setting.
Europe vascular closure device industry is experiencing substantial growth and will expand at 6.3% CAGR throughout 2023-2032. Europe has a growing aging population, leading to increased cardiovascular procedures. Stringent regulations promoting patient safety and the adoption of advanced medical technologies have fueled the demand for safer and more efficient closure methods. Additionally, expanding awareness among healthcare professionals and the presence of key market players in the region contribute to the industry's robust growth in Europe.